Bright Minds Biosciences Inc (NASDAQ:DRUG) traded at $41.80 at close of the session on current trade day and made a downward move of -8.57% on its previous day’s price.
Looking at the stock we see that its previous close was $45.72 and the beta (5Y monthly) reads 0.494 with the day’s price range being $40.3047 – $46.7151. In terms of its 52-week price range, DRUG has a high of $79.02 and a low of $0.93. The company’s stock has gained about 16.37% over that past 30 days.
Bright Minds Biosciences Inc has a market cap of $294.27 million and is expected to release its quarterly earnings report in March.
On the other hand, looking at the outlook for the DRUG stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy.
Looking further, we note the current price level is 11.57% off its SMA20 and 8.93% from its 50-day simple moving average. The RSI (14) is pointing at 56.23 while the volatility over the past week is 10.20% and jumps to 9.32% over the past one month. The beta value is -6.69, while the average true range (ATR) is currently pointing at 3.57. The average price target for the stock over the next 12 months is $85, with the estimates having a low of $85 and a high of $85. These price ends are -103.35% and -103.35% off the current price level respectively, although investors could be excited at the prospect of a -103.35% if the DRUG share price touches on the median price of $85.
Coming back to Bright Minds Biosciences Inc (NASDAQ:DRUG), we note that the average 3-month trading volume was 114.35K, while that of the preceding 10-day period stands at 67440.0. Current shares outstanding are 6.99 million.
The insiders hold 26.81% of the company’s shares while institutions hold 58.92%. The data shows that short shares as of 2025-01-31, stood at 0.14 million at a short ratio of 1.49. This represents a 287.00 short interest in shares outstanding on 2025-01-31. Shares short fall in January from the previous month at 0.18 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 16.05% up in year-to-date price movement.
